**IDO1 Inhibitor**

PF-06840003 is an investigational, small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an immunosuppressive enzyme that is overexpressed in a wide range of cancers.

**MECHANISM OF ACTION**

IDO1 may induce immunosuppression through degradation of the amino acid tryptophan, an important regulator of innate and adaptive immunity, and is also believed to cause resistance to cancer-fighting immune checkpoint inhibitor agents. The inhibition of IDO1 may help restore immune surveillance of tumors, potentially leading to the elimination of IDO1-expressing tumor cells. PF-06840003 is thought to work by targeting and binding to IDO1, increasing and restoring the proliferation and activation of various immune cells and reducing tumor-associated regulatory T cells (Tregs) that inhibit an immune response.

**THE POTENTIAL OF IDO1 INHIBITION**

- PF-06840003 has demonstrated anti-tumor activity in multiple preclinical tumor models when administered in combination with immune checkpoint inhibitors.¹
- PF-06840003 was exclusively licensed from iTeos to Pfizer in December 2014 when the companies entered into a license and collaboration agreement to develop therapeutics targeting the tumor immune environment.

**CLINICAL STUDIES**

Pfizer is exploring the potential of PF-06840003 to determine:

- Maximum tolerated dose
- Safety and efficacy profile
- Therapeutic potential

**ONGOING STUDIES**

- Data is currently being evaluated from a Phase 1 first-in-patient dose escalation study evaluating the safety and tolerability of PF-06840003 in patients with brain cancer (malignant gliomas) (NCT02764151).²

**REFERENCES**
